Edgar Filing: NOVAVAX INC - Form 4

NOVAVAX Form 4											
September 22, 2016 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue				CURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANGES IN BENEFICIAL OWNERSHIP OF SECURITIES on 16(a) of the Securities Exchange Act of 1934, c Utility Holding Company Act of 1935 or Section					OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5		
See Instr 1(b).	ruction	30(h) c	of the Ir	ivestment	t Company	/ Act	of 1940)			
(Print or Type	Responses)										
DOUGLAS RICHARD Symbol				II				5. Relationship of Reporting Person(s) to Issuer			
(Last) C/O NOVA FIRSTFIEI	VAX, INC., 20	Middle)	3. Date c	of Earliest T Day/Year)	L .	I	-	(Check _X_ Director Officer (give ti pelow)) Owner r (specify	
(Street) 4. If A				(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
	SBURG, MD 208							Form filed by Mo Person	ore than One Rej	porting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative S	ecurit	ties Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Day	Date, if	3. Transactio Code (Instr. 8) Code V	4. Securitie for Disposed (Instr. 3, 4 a Amount	l of (D	Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	09/21/2016			Р	100,000	А	\$ 1.7201 (1)	350,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: NOVAVAX INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
DOUGLAS RICHARD C/O NOVAVAX, INC. 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878	Х					
Signatures						
/s/ John A. Herrmann III, Attorney-in-Fact		09/22/2016				
**Signature of Reporting Person		Da	ate			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.715 to
 \$1.73, inclusive. The reporting person undertakes to provide Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the

range set forth in this footnote. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.